MANKIND.NS Profit & Loss
Mankind Pharma Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 23:37
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹87.49 Bn | ₹103.35 Bn | ₹122.07 Bn | ₹142.78 Bn | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹1.29 Bn | ₹2.81 Bn | ₹5.37 Bn | ₹3.59 Bn | OtherIncome |
| Total Income | ₹88.78 Bn | ₹106.16 Bn | ₹127.44 Bn | ₹146.36 Bn | Income |
| Cost of Materials Consumed | ₹18.14 Bn | ₹18.54 Bn | ₹20.16 Bn | ₹22.88 Bn | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹8.09 Bn | ₹14.10 Bn | ₹16.56 Bn | ₹17.28 Bn | PurchasesOfStockInTrade |
| Changes in Inventories | ₹2.91 Bn | ₹-0.54 Bn | ₹-1.83 Bn | ₹0.36 Bn | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹19.18 Bn | ₹22.75 Bn | ₹26.92 Bn | ₹31.84 Bn | EmployeeBenefitExpense |
| Finance Costs | ₹0.44 Bn | ₹0.34 Bn | ₹4.29 Bn | ₹6.39 Bn | FinanceCosts |
| Depreciation and Amortisation | ₹3.26 Bn | ₹3.98 Bn | ₹6.21 Bn | ₹8.86 Bn | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹20.17 Bn | ₹23.15 Bn | ₹30.08 Bn | ₹34.24 Bn | OtherExpenses |
| Total Expenses | ₹72.19 Bn | ₹82.31 Bn | ₹102.40 Bn | ₹121.86 Bn | Expenses |
| Profit Before Exceptional Items and Tax | ₹16.59 Bn | ₹23.84 Bn | ₹25.04 Bn | ₹24.51 Bn | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | ₹-1.30 Bn | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹16.59 Bn | ₹23.84 Bn | ₹25.04 Bn | ₹23.21 Bn | ProfitBeforeTax |
| Tax Expense | ₹3.62 Bn | ₹4.58 Bn | ₹5.10 Bn | ₹3.95 Bn | TaxExpense |
| Net Profit (incl. minority interest) | ₹13.10 Bn | ₹19.42 Bn | ₹20.11 Bn | ₹19.38 Bn | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹12.82 Bn | ₹19.13 Bn | ₹19.86 Bn | ₹19.13 Bn | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹32.00 | ₹47.75 | ₹49.28 | ₹46.35 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹32.00 | ₹47.68 | ₹49.19 | ₹46.28 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from MANKIND.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).